Legacy Flip




		
	        
603article: Multiple Myeloma and the MMRF CoMMpass Study: Revolutionizing Clinical Trial Data Dissemination A Panel Discussion With the Researchers
603article: Redesigning Clinical Trials Necessary to Improve Odds of Finding Effective Targeted Agents in the Genomic Era
601article: To PARP or Not to PARP – What Is the Question? Perspective on the First “Disappointment” With a New Drug Class
601article: Genomic Sequencing Uncovers the Genetic Landscape of Primary CNS Lymphoma: Will likely lead to new targeted therapies for an incurable malignancy
601article: Bevacizumab Maintenance Improves Survival in mCRC, but Added Erlotinib Is of No Value
601article: Olaparib Maintenance Therapy Slows Progression in Patients With Ovarian Cancer and BRCA Mutations
601article: Ponatinib Given Early May Stem Resistance in CML
601article: Genetic Susceptibility to Renal Cell Carcinoma
601article: Pathways Creating More and More Value
601article: Genomic Sequencing Assay Potentially a Game Changer
601article: Utilizing a Personalized Diagnostic in a Class of Hodgkin Lymphoma Patients:

An Interview With Lawrence M. Weiss, MD, of Clarient Diagnostic Services, Inc.

601article: How Do Melanoma Experts Use the New Agents?
601article: Illustrating the New Era of Personalized Medicine
600article: The Role of Biosimilars in Oncology: A Physician’s Perspective
600article: The Role of Biosimilars in Oncology: A Pharmacist’s Perspective
600article: The Role of Biosimilars in Oncology: A Nurse’s Perspective
600article: Understanding the Value of Biosimilars in Oncology
599article: The Role of Immunotherapies in Personalized Medicine
599article: Immunotherapy in Cancer Care: Personalized or Population-Based Medicine…and the Janusian Factor
599article: Ten Years of Tamoxifen Is Superior to 5 Years in ER+ Breast Cancer
599article: Multiple Myeloma: Novel Agents Emerge in Initial Therapy, Refractory Setting
599article: ASCO President Focuses on Bridges to Conquer Cancer
599article: Immune-Related Endocrinopathies Associated With Ipilimumab Therapy
599article: Providing Molecular Profiling for Patients With Ovarian Cancer:

An Interview with Laura Shawver, PhD, of The Clearity Foundation

599article: Antiangiogenic Tyrosine Kinase Inhibitors and Their Diverse Spectra of Inhibitory Activity: Implications for Personalized Therapy in Renal Cell Carcinoma
598article: The Importance of Cancer Survivorship Care Plans: A Physician’s Perspective
598article: The Importance of Cancer Survivorship Care Plans: A Pharmacist’s Perspective
598article: The Importance of Cancer Survivorship Care Plans: A Nurse’s Perspective
598article: The Importance of Survivorship Care Plans
595article: Trouble at the Beginning: Diagnostic Acumen and the Relentless Search for Red Flags
595article: Budget Impact Model: Epigenetic Assay Can Help Avoid Unnecessary Repeated Prostate Biopsies and Reduce Healthcare Spending
595article: Gene Profiling in Colon Cancer: How to Integrate Profiling Into Practice
595article: Personalized Medicine and Value: The Intersection of Science and Financial Viability
595article: A Path Toward Pancreatic Cancer Predictive Biomarkers
595article: First-in-Class PI3K Inhibitor Shows Remarkable Phase 1 Results in CLL
595article: Combination Immunotherapy Shows Promise in Advanced Melanoma
595article: Anti–PD-L1 Drug Achieves Response in Variety of Tumors
595article: Personalized Medicine in the Public Arena: Managing Expectations
594article: Proceedings From a Post-IMW Roundtable
594article: Letter from the Editor June 2013
593article: Bendamustine: Progress in Clinical Investigations
593article: The Developing Treatment Role of Bendamustine
593article: Advances in Bendamustine Clinical Trials
593article: Novel Approaches in the Treatment of Hematologic Malignancies Utilizing Bendamustine
591article: Personalized Treatment Planning: A Pharmacist’s Perspective
591article: Personalized Treatment Planning: A Nurse’s Perspective
591article: Personalized Treatment Planning
591article: Personalized Treatment Planning: A Physician’s Perspective
586article: Crizotinib and Colorectal Cancer – A Couple to Be Tested?
588article: Safety of Bendamustine in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
588article: Safety of Bendamustine in Treatment of CLL and NHL
588article: Toxicity of Bendamustine Therapy
586article: The MHealth Factor: A Bioinformatics Platform for Arming the Oncology Personalized Medicine Revolution
586article: Current Treatment of Myelofibrosis: How Far We Have Come and How Far We Have Yet to Go
586article: Sequential Therapy for Renal Cell Carcinoma
586article: Personalizing Cancer Care, Policy, and the Payer Perspective:

An Interview with Peter F. Hayes of Healthcare Solutions

586article: Higher HER2 Expression Leads to Better Outcomes With T-DM1 in HER2-Positive Metastatic Breast Cancer
586article: Highlights From the American Association for Cancer Research Annual Meeting
586article: The Changing Oncology Landscape: Evolution or Revolution?
586article: NCCN Updates Its Clinical Practice Guidelines
587article: Hospice Care Options: A Physician’s Perspective
587article: Hospice Care Options: A Nurse’s Perspective
587article: Hospice Care Options: A Pharmacist’s Perspective
587article: Hospice Care: Providing Critical Support to Patients and Families
586article: Personalized Medicine in Oncology: Providing Insights to Optimally Utilize Personalized Medicine Concepts
588article: Safety of Bendamustine in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
580article: The Affordable Care Act and Oncology Personalized Medicine: Compatibility and the Governing Dynamics of Healthcare
580article: The Doctor Won’t See You Now. He’s Clocked Out.
580article: The RomneyCare Bill Comes Due
580article: Introducing the Third Annual Conference of the Association for Value-Based Cancer Care
580article: Promoting the Adoption of Personalized Medicine Concepts:

An Interview with Edward Abrahams, PhD, of the Personalized Medicine Coalition

580article: Physician-Reported Clinical Utility of the 92-Gene Molecular Classifier in Tumors With Uncertain Diagnosis Following Standard Clinicopathologic Evaluation
580article: Prostate and Kidney Cancer News From the 2013 Genitourinary Cancers Symposium
580article: Targeted Therapies Added to Docetaxel Do Not Extend Survival in Metastatic Prostate Cancer
580article: SNPs Identified for Further Study in Association With QOL in Men With Prostate Cancer Treated With Radiation
580article: Comprehensive Gene Analysis Allows for Personalization of 5-FU to Reduce Risk of Toxicity
580article: Liposomal Vincristine Allows for Greater Dose Density Without Increased Neurotoxicity
580article: Information Overload – the Search for Clinical Relevance in the Oncology Literature
583article: A Physician’s Perspective on Pain Management
583article: Clinical Decision Making in Assessing and Treating Cancer Pain
583article: Classifying and Managing Pain in the Oncology Patient
583article: Introduction to Oncology Pain Management
582article: A Commentary on the Efficacy of Bendamustine in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
582article: Efficacy of Bendamustine in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
582article: Efficacy of Bendamustine in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
582article: Bendamustine in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma
585article: Molecular Subtyping Reclassifies Early Breast Cancer in a Proportion of Patients
585article: Predicting Risk of Significant Side Effects Made Possible by OnPART
585article: Women With Triple-Negative Breast Cancer Highly Likely to Carry BRCA1 Gene
585article: Mayo Clinic Researchers Propose Screening Algorithm for HER2 in Esophageal Cancer
585article: In Colon Cancer, Genomic Classifiers Aid in Prognosis
585article: Progress in Personalized Approaches to Colorectal Cancer
585article: Applying Personalized Medicine in the Overall Healthcare Environment
585article: The Supportive Face of the FDA in the Advancement of Personalized Medicine
585article: Personalized Medicine Highlights From ASH 2012
585article: The Drawn Out Process of the Medical Lawsuit
585article: Next-Generation Sequencing:

An Interview with Michael J. Pellini, MD, of Foundation Medicine

585article: Resistance to Targeted Molecular Therapies in NSCLC
579article: Stakeholder’s Perspective: Pharmacy Considerations
579article: Stakeholder’s Perspective: Nursing Considerations